PFIZER INC Impairment of Intangible Assets (Excluding Goodwill)
PFIZER INC (PFE) reported Impairment of Intangible Assets (Excluding Goodwill) of $4.33 billion for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-08-04
- PFIZER INC impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $4.36B, a 48.10% increase year-over-year.
- PFIZER INC impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-28 was $260.00M.
- PFIZER INC impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-29 was $93.00M, a 61.25% decline year-over-year.
- PFIZER INC impairment of intangible assets (excluding goodwill) for the quarter ending 2025-03-30 was $224.00M, a 105.50% increase year-over-year.
- PFIZER INC impairment of intangible assets (excluding goodwill) for fiscal 2025 was $4.94B, a 49.92% increase from fiscal 2024.
- PFIZER INC impairment of intangible assets (excluding goodwill) for fiscal 2024 was $3.29B, a 9.83% increase from fiscal 2023.
- PFIZER INC impairment of intangible assets (excluding goodwill) for fiscal 2023 was $3.00B, a 612.59% increase from fiscal 2022.
- PFIZER INC impairment of intangible assets (excluding goodwill) for fiscal 2022 was $421.00M.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month as first filed | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month as first filed | Impairment of Intangible Assets (Excluding Goodwill) 12 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-28 | $4.33B 10-Q · filed 2026-08-04 | ||||||
| 2025-12-31 | $4.36B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.62B derived: sum of 2 quarters · filed 2026-02-26 | $4.72B derived: sum of 3 quarters · filed 2026-02-26 | $4.94B 10-K · filed 2026-02-26 | |||
| 2025-09-28 | $260.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $353.00M derived: sum of 2 quarters · filed 2025-11-04 | $577.00M 10-Q · filed 2025-11-04 | $3.52B derived: sum of 4 quarters · filed 2025-11-04 | |||
| 2025-06-29 | $93.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $317.00M 10-Q · filed 2025-08-05 | $3.26B derived: sum of 3 quarters · filed 2025-08-05 | $3.26B derived: sum of 4 quarters · filed 2025-08-05 | |||
| 2025-03-30 | $224.00M 10-Q · filed 2025-05-05 | $3.17B derived: sum of 2 quarters · filed 2025-05-05 | $3.17B derived: sum of 3 quarters · filed 2025-05-05 | $3.41B derived: sum of 4 quarters · filed 2025-05-05 | |||
| 2024-12-31 | $2.95B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.95B derived: sum of 2 quarters · filed 2025-02-27 | $3.19B derived: sum of 3 quarters · filed 2025-02-27 | $3.29B 10-K · filed 2025-02-27 | |||
| 2024-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $240.00M derived: sum of 2 quarters · filed 2024-11-04 | $349.00M 10-Q · filed 2024-11-04 | $3.10B derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $240.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $349.00M 10-Q · filed 2024-08-05 | $3.10B derived: sum of 3 quarters · filed 2026-02-26 | $3.10B derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $109.00M 10-Q · filed 2024-05-08 | $2.86B derived: sum of 2 quarters · filed 2026-02-26 | $2.86B derived: sum of 3 quarters · filed 2026-02-26 | $2.86B derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $2.75B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.75B derived: sum of 2 quarters · filed 2026-02-26 | $2.75B derived: sum of 3 quarters · filed 2026-02-26 | $3.00B 10-K · filed 2026-02-26 | $3.01B 10-K · filed 2024-02-22 | ||
| 2023-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $248.00M 10-Q · filed 2023-11-08 | ||||
| 2023-07-02 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $248.00M 10-Q · filed 2023-08-09 | |||||
| 2023-04-02 | $248.00M 10-Q · filed 2023-05-10 | ||||||
| 2022-12-31 | $421.00M 10-K · filed 2023-02-23 | ||||||
| 2020-12-31 | $800.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.70B 10-K · filed 2023-02-23 | $1.69B 10-K · filed 2021-02-25 | ||||
| 2020-09-27 | $900.00M 10-Q · filed 2020-11-05 | ||||||
| 2020-03-29 | $130.00M 10-Q · filed 2020-05-07 | $2.92B derived: sum of 2 quarters · filed 2022-02-24 | $2.92B derived: sum of 3 quarters · filed 2022-02-24 | $2.93B derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $2.79B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.79B derived: sum of 2 quarters · filed 2022-02-24 | $2.80B derived: sum of 3 quarters · filed 2022-02-24 | $2.80B 10-K · filed 2022-02-24 | $2.77B 10-K · filed 2020-02-27 | ||
| 2019-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $10.00M derived: sum of 2 quarters · filed 2019-11-07 | $10.00M 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $10.00M 10-Q · filed 2019-08-08 | $10.00M 10-Q · filed 2019-08-08 | |||||
| 2019-03-31 | $130.00M 10-Q · filed 2019-05-09 | ||||||
| 2018-12-31 | $3.10B 10-K · filed 2021-02-25 | $3.10B 10-K · filed 2019-02-28 | |||||
| 2018-07-01 | $31.00M 10-Q · filed 2019-11-07 | $31.00M 10-Q · filed 2019-08-08 | |||||
| 2017-12-31 | $337.00M 10-K · filed 2020-02-27 | ||||||
| 2016-12-31 | $102.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $228.00M derived: sum of 2 quarters · filed 2019-02-28 | $869.00M derived: sum of 3 quarters · filed 2019-02-28 | $869.00M 10-K · filed 2019-02-28 | |||
| 2016-10-02 | $126.00M 10-Q · filed 2017-11-09 | $767.00M derived: sum of 2 quarters · filed 2017-11-09 | $767.00M 10-Q · filed 2017-11-09 | ||||
| 2016-07-03 | $641.00M 10-Q · filed 2017-08-10 | $641.00M 10-Q · filed 2017-08-10 | |||||
| 2015-12-31 | $160.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $323.00M derived: sum of 2 quarters · filed 2018-02-22 | $323.00M 10-K · filed 2018-02-22 | ||||
| 2015-09-27 | $163.00M 10-Q · filed 2016-11-10 | $163.00M 10-Q · filed 2016-11-10 | |||||
| 2014-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $282.00M derived: sum of 2 quarters · filed 2017-02-23 | $282.00M derived: sum of 3 quarters · filed 2017-02-23 | $396.00M 10-K · filed 2017-02-23 | |||
| 2014-09-28 | $242.00M 10-Q · filed 2015-11-05 | $242.00M derived: sum of 2 quarters · filed 2015-11-05 | $356.00M 10-Q · filed 2015-11-05 | $485.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $114.00M 10-Q · filed 2014-08-07 | $243.00M derived: sum of 3 quarters · filed 2016-02-29 | $428.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-30 | $114.00M 10-Q · filed 2014-05-08 | $243.00M derived: sum of 2 quarters · filed 2016-02-29 | $428.00M derived: sum of 3 quarters · filed 2016-02-29 | $917.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $129.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $314.00M derived: sum of 2 quarters · filed 2016-02-29 | $803.00M derived: sum of 3 quarters · filed 2016-02-29 | $803.00M 10-K · filed 2016-02-29 | |||
| 2013-09-29 | $185.00M 10-Q · filed 2014-11-06 | $674.00M derived: sum of 2 quarters · filed 2014-11-06 | $674.00M 10-Q · filed 2014-11-06 | $1.45B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2013-06-30 | $489.00M 10-Q · filed 2013-08-09 | $489.00M 10-Q · filed 2014-08-07 | $475.00M 10-Q · filed 2013-08-09 | $1.26B derived: sum of 3 quarters · filed 2015-02-27 | $1.76B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $395.00M 10-Q · filed 2013-05-10 | $773.00M derived: sum of 2 quarters · filed 2015-02-27 | $1.27B derived: sum of 3 quarters · filed 2015-02-27 | $1.32B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $378.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $872.00M derived: sum of 2 quarters · filed 2015-02-27 | $925.00M derived: sum of 3 quarters · filed 2015-02-27 | $835.00M 10-K · filed 2015-02-27 | $872.00M 10-K · filed 2013-02-28 | ||
| 2012-09-30 | $494.00M 10-Q · filed 2012-11-09 | $547.00M derived: sum of 2 quarters · filed 2012-11-09 | $457.00M 10-Q · filed 2013-11-08 | $494.00M 10-Q · filed 2012-11-09 | $1.19B derived: sum of 4 quarters · filed 2014-02-28 | ||
| 2012-07-01 | $53.00M 10-Q · filed 2012-08-09 | $449.00M 10-Q · filed 2013-08-09 | $697.00M derived: sum of 3 quarters · filed 2014-02-28 | $802.00M derived: sum of 4 quarters · filed 2014-02-28 | |||
| 2012-04-01 | $395.00M 10-Q · filed 2013-05-10 | $644.00M derived: sum of 2 quarters · filed 2014-02-28 | $749.00M derived: sum of 3 quarters · filed 2014-02-28 | $1.07B derived: sum of 4 quarters · filed 2014-02-28 | |||
| 2011-12-31 | $249.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $354.00M derived: sum of 2 quarters · filed 2014-02-28 | $674.00M derived: sum of 3 quarters · filed 2014-02-28 | $834.00M 10-K · filed 2014-02-28 | $851.00M 10-K · filed 2013-02-28 | ||
| 2011-10-02 | $105.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $425.00M derived: sum of 2 quarters · filed 2012-11-09 | $585.00M 10-Q · filed 2012-11-09 | ||||
| 2011-07-03 | $320.00M 10-Q · filed 2012-08-09 | $480.00M 10-Q · filed 2012-08-09 | |||||
| 2010-12-31 | $1.79B 10-K · filed 2013-02-28 | $1.80B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |